Table 1 Patient characteristics and treatment
| Â | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|---|---|---|---|---|---|
Age (years) | 53 | 71 | 62 | 76 | 67 |
Sex | Male | Male | Male | Female | Female |
Comorbidities | No | CAD, s/p CABG, schizophrenia, depression | Atrial fibrillation, hypertension | Diabetes, hypertension, s/p stroke | Diabetes, hypertension, CKD stage V*, obesity stage II |
Antibiotic therapy during the course of the disease | Piperacillin/tazobactam#, azithromycin, meropenem, vancomycin, ceftazidime, metronidazole | Piperacillin/tazobactam#, azithromycin, meropenem, vancomycin | Piperacillin/tazobactam#, azithromycin, meropenem, vancomycin | Piperacillin/tazobactam#, meropenem, flucloxacillin | Piperacillin/tazobactam# |
Antifungal therapy during the course of the disease | Caspofungin# | Caspofungin# | Caspofungin# | Caspofungin# | Caspofungin# |
Antiviral and immunomodulatory therapy during the course of the disease | Hydroxychloroquine#, lopinavir/ritonavir, maraviroc#, aciclovir (for HSV) | Hydroxychloroquine#, maraviroc#, aciclovir (for HSV) | Maraviroc#, aciclovir (for HSV), ganciclovir (for CMV) | Maraviroc# | Maraviroc#, aciclovir (for HSV) |
Other therapy during the course of the disease | Tocilizumab, interferon, prednisolone | Â | Immunoglobulins, prednisolone, convalescent serum | Convalescent serum | Â |
Time from symptom to PE (days) | 12 | 9 | 16 | 17 | 11 |
Time from admission to PE (days) | 6 | 4 | 8 | 10 | 5 |
Processed plasma volume (L) | 3.60 3.66 (2) | 3.38 | 3.02 2.93 (2) | 3.17 | 3.51 3.40 (2) |
Clinical outcome as of June 15, 2020 | Extubated and spontaneous breathing, discharged from hospital | Died | Extubated and spontaneous breathing, discharged from hospital | Died | Extubated and spontaneous breathing, discharged from hospital |